awmsg logo



abiraterone acetate (Zytiga®)


Reference No. 1794

Publication date:
25/09/2014


Appraisal information

abiraterone acetate (Zytiga®) 250 mg tablet


Company: Janssen-Cilag Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 09/04/2014
AWMSG meeting date: 11/06/2014
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: 1614
Ratification by Welsh Government: 01/09/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA387) NICE GUIDANCE ISSUED APRIL 2016 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology). Abiraterone acetate (Zytiga®) with prednisone or prednisolone is not recommended for use within NHS Wales for the treatment of metastatic castration-resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. The case for cost effectiveness has not been proven.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download